未分化多形性肉瘤(UPS):流行病學洞察(2030年為止的預測)

本報告提供世界主要7個國家(美國，歐洲5個國家(德國，法國，義大利，西班牙，英國)，日本)的未分化多形性肉瘤(UPS)的相關調查，提供流行病學及預測，各市場區隔的病例，診斷案例等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 疾病的背景和概要

• 概要
• 徵兆與症狀
• 病理學
• 危險因素
• 診斷

第4章 患者的治療過程

第5章 流行病學和患者人口

• 流行病學的主要調查結果
• 前提條件與理論的根據:主要7個國家
• 流行病學方案:主要7個國家
  • 流行病學方案(2017-2030)
• 美國流行病學
• 各流行病學歐洲5個國家
  • 德國流行病學
  • 法國流行病學
  • 義大利流行病學
  • 西班牙流行病學
  • 英國流行病學
• 日本流行病學

第6章 治療流程，目前治療，及醫務

• 治療和管理
• 治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

• 參考文獻
• 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

DelveInsight's 'Undifferentiated Pleomorphic Sarcoma (UPS) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Undifferentiated Pleomorphic Sarcoma (UPS) Understanding

The DelveInsight Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology report gives a thorough understanding of the Undifferentiated Pleomorphic Sarcoma (UPS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Undifferentiated Pleomorphic Sarcoma (UPS) in the US, Europe, and Japan. The report covers the detailed information of the Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology scenario in seven major countries (US, EU5, and Japan).

Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Perspective by DelveInsight

The Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Undifferentiated Pleomorphic Sarcoma (UPS) Detailed Epidemiology Segmentation

The Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology covered in the report provides historical as well as forecasted Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Undifferentiated Pleomorphic Sarcoma (UPS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

• The Undifferentiated Pleomorphic Sarcoma (UPS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Undifferentiated Pleomorphic Sarcoma (UPS) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Undifferentiated Pleomorphic Sarcoma (UPS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Undifferentiated Pleomorphic Sarcoma (UPS)
• The report provides the segmentation of the Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology

Report Highlights:

• 11-Year Forecast of Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology
• 7MM Coverage
• Total Cases of Undifferentiated Pleomorphic Sarcoma (UPS)
• Total Cases of Undifferentiated Pleomorphic Sarcoma (UPS) according to segmentation
• Diagnosed cases of Undifferentiated Pleomorphic Sarcoma (UPS)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Undifferentiated Pleomorphic Sarcoma (UPS) ?
• What are the key findings pertaining to the Undifferentiated Pleomorphic Sarcoma (UPS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Undifferentiated Pleomorphic Sarcoma (UPS) across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of the Undifferentiated Pleomorphic Sarcoma (UPS) ?
• What are the currently available treatments of Undifferentiated Pleomorphic Sarcoma (UPS) ?

Reasons to buy:

• The Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Undifferentiated Pleomorphic Sarcoma (UPS) market
• Quantify patient populations in the global Undifferentiated Pleomorphic Sarcoma (UPS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Undifferentiated Pleomorphic Sarcoma (UPS) therapeutics in each of the markets covered
• Understand the magnitude of Undifferentiated Pleomorphic Sarcoma (UPS) population by its epidemiology
• The Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Undifferentiated Pleomorphic Sarcoma (UPS)

3. Undifferentiated Pleomorphic Sarcoma (UPS) : Disease Background and Overview

• 3.1. Introduction
• 3.2. Sign and Symptoms
• 3.3. Pathophysiology
• 3.4. Risk Factors
• 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

• 5.1. Epidemiology Key Findings
• 5.2. Assumptions and Rationale: 7MM
• 5.3. Epidemiology Scenario: 7MM
  • 5.3.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in the 7MM (2017- 2030)
• 5.4. United States Epidemiology
  • 5.4.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in the United States (2017- 2030)
• 5.5. EU-5 Country-wise Epidemiology
  • 5.5.1. Germany Epidemiology
    • 5.5.1.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in Germany (2017- 2030)
  • 5.5.2. France Epidemiology
    • 5.5.2.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in France (2017- 2030)
  • 5.5.3. Italy Epidemiology
    • 5.5.3.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in Italy (2017- 2030)
  • 5.5.4. Spain Epidemiology
    • 5.5.4.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in Spain (2017- 2030)
  • 5.5.5. United Kingdom Epidemiology
    • 5.5.5.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in the United Kingdom (2017-2030)
• 5.6. Japan Epidemiology
  • 5.6.1. Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

• 6.1. Undifferentiated Pleomorphic Sarcoma (UPS) Treatment and Management
• 6.2. Undifferentiated Pleomorphic Sarcoma (UPS) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

• 9.1. Bibliography
• 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

• Table 1: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in 7MM (2017-2030)
• Table 2: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in 7MM (2017-2030)
• Table 3: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in the United States (2017-2030)
• Table 4: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in the United States (2017-2030)
• Table 5: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Germany (2017-2030)
• Table 6: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Germany (2017-2030)
• Table 7: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in France (2017-2030)
• Table 8: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in France (2017-2030)
• Table 9: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Italy (2017-2030)
• Table 10: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Italy (2017-2030)
• Table 11: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Spain (2017-2030)
• Table 12: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Spain (2017-2030)
• Table 13: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in the United Kingdom (2017-2030)
• Table 14: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Table 15: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Japan (2017-2030)
• Table 16: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

• Figure 1: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in 7MM (2017-2030)
• Figure 2: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in 7MM (2017-2030)
• Figure 3: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in the United States (2017-2030)
• Figure 4: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in the United States (2017-2030)
• Figure 5: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Germany (2017-2030)
• Figure 6: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Germany (2017-2030)
• Figure 7: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in France (2017-2030)
• Figure 8: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in France (2017-2030)
• Figure 9: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Italy (2017-2030)
• Figure 10: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Italy (2017-2030)
• Figure 11: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Spain (2017-2030)
• Figure 12: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Spain (2017-2030)
• Figure 13: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in the United Kingdom (2017-2030)
• Figure 14: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Figure 15: Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology in Japan (2017-2030)
• Figure 16: Undifferentiated Pleomorphic Sarcoma (UPS) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report